Glaukos Corp (GKOS)
112.72
+2.02
(+1.82%)
USD |
NYSE |
May 31, 16:00
112.89
+0.17
(+0.15%)
After-Hours: 20:00
Glaukos Research and Development Expense (Annual): 138.77M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 138.77M |
| December 31, 2022 | 123.27M |
| December 31, 2021 | 101.00M |
| December 31, 2020 | 85.39M |
| December 31, 2019 | 68.31M |
| December 31, 2018 | 49.68M |
| Date | Value |
|---|---|
| December 31, 2017 | 38.90M |
| December 31, 2016 | 29.22M |
| December 31, 2015 | 25.05M |
| December 31, 2014 | 19.20M |
| December 31, 2013 | 15.51M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
68.31M
Minimum
2019
138.77M
Maximum
2023
103.35M
Average
101.00M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp | 1.414B |
| Accuray Inc | 57.13M |
| Alphatec Holdings Inc | 70.12M |
| Asensus Surgical Inc | 37.02M |
| iRhythm Technologies Inc | 60.24M |